Biome Investor Presentation June 2026
Released
Released
Announcement PDF
BIOME AUSTRALIA · ASX: BIO 1
1
Biome Australia
H1 FY26 RESULTS & COMPANY PRESENTATION
Biome Australia
Australia’s #1 fastest-growing probiotic brand —
clinically-backed, profitable, and scaling.
Blair Vega Norfolk · Founder & Managing Director
ASX: BIO
The Microbiome Health Company
Biome Australia Group
Our mission
To prevent disease, improve health
outcomes and quality of life, and
make our products accessible to all
BIOME AUSTRALIA · ASX: BIO 3
3
Biome Australia
INVESTMENT HIGHLIGHTS
Profitable, clinically-differentiated, and scaling
Biome develops, owns and clinically validates proprietary probiotic strains, sold through pharmacy and practitioner
channels under the Activated Probiotics® and Activated Therapeutics® brands.
Australia’s #1 fastest-growing probiotic brand
Leader by revenue in community pharmacy, with 100% of the range in growth.
A record, profitable first half
H1 FY26 was the eighth consecutive EBITDA-positive quarter, building on FY25’s first full-year net profit.
Clinically differentiated
30+ randomised controlled trials, plus a proprietary strain — BMB18 — now in a 240-participant human trial.
Scaling at home and abroad
~7,500 points of sale and five international markets live, tracking to the Vision 2027 plan.
BIOME AUSTRALIA · ASX: BIO 4
4
Biome Australia
OUR JOURNEY
From start-up to Australia’s fastest-growing probiotic brand
Revenue has compounded at ~86% a year from FY20 to FY25 — and FY26 has opened with a record half.
FY20
$830k
First full year of sales
→
FY25
$18.4m
Revenue, +41.6% — first net profit
→
FY26
Record H1
$12.4m revenue, +40% PCP
Clinically-backed range
Built on 30+ randomised controlled trials.
Scaled distribution
From a standing start to ~7,500 points of sale across pharmacy.
Profitable and compounding
Eight consecutive EBITDA-positive quarters.
International reach
Live in five markets, with international sales up 69% in FY25.
BIOME AUSTRALIA · ASX: BIO 5
5
Biome Australia
H1 FY26 FINANCIAL SCORECARD
Record results across every key metric
REVENUE
$12.40m
+40% vs PCP
ADJUSTED EBITDA
$1.47m
8th consecutive quarter
NET PROFIT
$1.18m
+172% vs PCP
GROSS MARGIN
61%
1H25: 61.0%
OPERATING CASH FLOW
$2.09m
$3.21m turnaround
EPS
0.53c
+165% vs PCP
BIOME AUSTRALIA · ASX: BIO 6
6
Biome Australia
OPERATING LEVERAGE
Earnings growing far faster than revenue
+40%
Revenue growth (PCP)
+172%
Net profit growth (PCP)
Profit is compounding more than four times faster than revenue — with gross
margin held at 61.1% and an eighth consecutive EBITDA-positive quarter.
BIOME AUSTRALIA · ASX: BIO 7
7
Biome Australia
REVENUE TRAJECTORY
Compounding revenue, now profitable
H1 FY26
$12.4m
Revenue · +40% PCP
$1.47m
Adj EBITDA (excl SBP)
FY25 — first full-year net profit. Eight
straight EBITDA-positive quarters.
FY20‒FY25 actual full-year revenue. H1 FY26 actual was $12.4m, up 40% on the prior corresponding half.
BIOME AUSTRALIA · ASX: BIO 8
8
Biome Australia
MANUFACTURING & MARGIN
Onshoring manufacturing — margin and working-capital upside
A binding supply & purchase agreement brings key manufacturing onshore —
structurally lifting gross margin and releasing working capital.
Gross-margin uplift
Increasing significantly from the strong
61% today commencing from FY27
Working-capital release
A shorter, local supply chain will up free significant
capital tied up in inventory, goods-in-transit and
shortens the cash-conversion cycle.
Supply security & Australian-made
Onshore production reduces lead times and import
dependency — aligned with Biome’s B Corp credentials.
The milestone
Binding agreement was executed on July 2 2026;
first onshore production from September 2026.
Draft — subject to execution of the agreement; figures to be confirmed. Do not circulate until signed and, if price-sensitive, announced to the ASX.
BIOME AUSTRALIA · ASX: BIO 9
9
Biome Australia
MARKET OPPORTUNITY
A large market — significant growth headroom
Global probiotics market ~US$75bn+ growing 7‒9% p.a.
Australian probiotics market ~A$600m
Biome today ~$25m*
← significant headroom
We hold a low-single-digit share of our home market today —
with 8,000-store distribution and five international markets still to convert.
*Annualised on H1 FY26 revenue. Market sizes are management estimates.
BIOME AUSTRALIA · ASX: BIO 10
10
Biome Australia
MARKET POSITION
Fastest-growing brand in pharmacy’s biggest category
#1 Community pharmacy (ex CW)
Largest probiotic brand in community pharmacy
by revenue — and the fastest growing.
#2 Terry White Chemmart Second-largest brand by revenue in largest category.
48%+ Priceline Pharmacy
Moving-annual-total (MAT) sales growth
and 5th
brand for profit in category.
#1 Wholesale (Symbion / API) 100% of the range in growth.
BIOME AUSTRALIA · ASX: BIO 11
11
Biome Australia
HOW WE WIN
Practitioner Only - High Value - Solution driven
Practitioner endorsement drives full-margin growth
1
Practitioner
education
→
2
Clinical
recommendation
→
3
Pharmacy purchase
→
4
Scan data validates
→
5
Category leadership
A pull model. Demand is created by clinical recommendation and validated
by scan data — full-margin growth, without promotional discounting.
BIOME AUSTRALIA · ASX: BIO 12
12
Biome Australia
PRODUCT PLATFORM
Two clinically-backed brand families
Activated Probiotics®
Condition-specific, practitioner-recommended
probiotics across the range.
Activated Therapeutics®
Selective, clinically-validated formulations
for targeted applications.
BIOME AUSTRALIA · ASX: BIO 13
13
Biome Australia
MARKET EXPANSION
Adjunct medication opportunities
Condition-specific range enables multiple products per patient, positioned alongside medical treatment.
ATC MEDICATION CATEGORY VOLUME (FY21) ACTIVATED PROBIOTICS PRODUCT & ADJUNCT USE
General Anti-infectives 10M scripts / yr Biome Advanced™ Probiotic
To help restore the balance of beneficial
gut bacteria after antibiotic use
Nervous System 48M scripts / yr Biome Lift™ Probiotic
To support healthy mood balance
and enhance sleep quality
Respiratory System 12M scripts / yr Biome Breathe™ Probiotic
To help stimulate a healthy
immune response in children
Dermatological 3M scripts / yr Biome Eczema™ Probiotic To help reduce the symptoms of mild eczema
Musculo-skeletal System 7M scripts / yr Biome Osteo™ Probiotic To help promote healthy bones in adults
Cardiovascular System 29M scripts / yr Biome Cholesterol™ Probiotic
To help support healthy cholesterol
levels in healthy adults
Source: PBS / Medicare prescription statistics, FY21. Activated Probiotics are recommended by practitioners as complementary to
medical treatment, not as alternatives — positioning Biome alongside medical
interventions rather than competing with mass-market supplements.
BIOME AUSTRALIA · ASX: BIO 14
14
Biome Australia
CLINICAL EVIDENCE
The clinical moat competitors can’t replicate
• 30+ randomised controlled trials on Biome’s finished products.
• Peer-reviewed publication, including in The Lancet.
• Evidence across mood & sleep, immune & respiratory, skin, bone,
cholesterol and children’s health.
• Practitioner-Only
• Hard to replicate — trials take years and capital, and earn the
practitioner trust that drives the pull model.
BIOME AUSTRALIA · ASX: BIO 15
15
Biome Australia
LEAD ASSET — BMB18
A proprietary strain in human clinical trial
BMB18 — Lactiplantibacillus plantarum
· 100% Biome-owned · DSM registered
• In-vitro results: immune modulation, oxidative-stress
reduction, gut-barrier integrity.
• 240-participant, double-blind, placebo-controlled
RCT with La Trobe University; commenced February
2026 (ANZCTR registered).
• Sits on an existing base of 30+ RCTs across
Biome’s finished products.
BIOME AUSTRALIA · ASX: BIO 16
16
Biome Australia
DISTRIBUTION
From 100 to a 7,500-store footprint
~7,500
Points of sale by end FY26
~12,000
Addressable AU locations
8,000
FY27 target (Vision 27)
Progress to the Vision 27 distribution target
Started at 100 stores 8,000 by FY27
Distribution has grown from 100 to over 7,000 points of sale, laddering toward
the Vision 27 target of 8,000 by FY27 — with roughly 12,000 addressable.
BIOME AUSTRALIA · ASX: BIO 17
17
Biome Australia
INTERNATIONAL
Five markets live; international sales up 69% in FY25 with careful
investments in FY26 to build the foundation with low run rate
AUSTRALIA
Established
Scaled domestic base
across pharmacy and
practitioner channels.
CANADA
Growing
Fullscript live alongside
Ecotrend; dedicated
team building the FY27
launch base.
IRELAND & UK
Launched
Partnerships building
across both markets, led
by Uniphar pharmacy
partnership in Ireland.
NEW ZEALAND
Launched
Live via the EBOS Group /
Pharmacy channel.
BIOME AUSTRALIA · ASX: BIO 18
18
Biome Australia
VISION 2027
The roadmap to FY27
FY25
DELIVERED
• First net profit ($214,656)
• Revenue $18.4m, +41.6%
• International sales +69%
• ~7,000 points of sale
→
FY26
IN PROGRESS
• H1 revenue $12.4m, +40% PCP
• 8th consecutive EBITDA+ quarter
• BMB18 RCT commenced (La Trobe)
• ~7,500 points of sale by year-end
→
FY27
TARGET
• $75m cumulative sales (FY25‒FY27)
• 8,000 points of sale
• International markets scaling
• BMB18 clinical trial readout
On track — FY25 delivered the first net profit; H1 FY26 is running +40% PCP into the plan.
BIOME AUSTRALIA · ASX: BIO 19
19
Biome Australia
H2 OUTLOOK & CATALYSTS
Near-term value drivers
Winter immunity campaign
Major above-the-line activation — outdoor, digital and
co-branded with key retail partners — timed to peak demand.
International momentum
Canada scaling with Fullscript; Ireland, UK and New Zealand
partnerships continuing to build.
BMB18 clinical trial
240-participant RCT underway with La Trobe University,
supporting proprietary product development and IP.
Category and range expansion
New therapeutic categories under evaluation across Activated
Probiotics and Activated Therapeutics.
BIOME AUSTRALIA · ASX: BIO 20
20
Biome Australia
INVESTMENT CASE
Why Biome
Category leader
#1 fastest-growing probiotic brand in
Australia’s biggest pharmacy category.
Premium-margin model
61% gross margin, sustained
without promotional discounting.
Operating leverage proven
First net profit delivered; eight
consecutive EBITDA-positive quarters.
Proprietary IP pipeline
BMB18 in human trial;
30+ RCTs across the range.
International optionality
Five markets live, sales up 69% —
Canada the next growth engine.
Fully-funded growth
Cash-generative and largely
self-funding the plan to Vision 27.
BIOME AUSTRALIA · ASX: BIO 21
21
Biome Australia
CAPITAL STRUCTURE
Snapshot & balance sheet
ASX code BIO
Share price 22.5c
Market capitalisation $51.5m
Shares on issue 228m
Performance rights / options Nil
Cash (Q3 FY26) $3.39m
Debt drawn (Q3 FY26) $2.12m
Undrawn facility $2.89m
52-week range 20c ‒ 63c
BALANCE SHEET
Net cash position, no dilution overhang
$3.39m cash against $2.12m drawn — with a further $2.89m
undrawn and no options or performance rights on issue.
TOP SHAREHOLDERS
Founder, management & staff 13%
Board 4%
High-net-worth investors 5% · 3.5%
Institutional funds 4% · 3.5% · 2.5%
Top 50 holders 57%
Market data and register as at 1 June 2026; cash and debt as at Q3 FY26.
BIOME AUSTRALIA · ASX: BIO 22
22
Biome Australia
THANK YOU
Profitable. Clinical.
Scaling.
Blair Vega Norfolk · Founder & Managing Director
Lauren Dwyer · Chief Financial Officer
corporate@biomeaustralia.com
biomeaustralia.com · activatedprobiotics.com.au
ASX: BIO
Certified B Corporation.
BIOME AUSTRALIA · ASX: BIO 24
24
Biome Australia
DISCLAIMER
This presentation and the information contained within it (the “information”) has
been prepared solely for the use and benefit of the person to whom it is provided
(the “recipient”).
It has been provided to the recipient on a strictly confidential basis solely for the
purpose of assisting the recipient to determine whether it may be interested in
participating in the investment opportunity described in this presentation
(“Opportunity”) and if so, to participate in that process, and may only be used for
that purpose.
This presentation contains selected information only and does not purport to
contain all of the information that may be relevant to the Opportunity.
The information is not a prospectus, disclosure document, product disclosure
statement or other offering document under Australian law or under any other law.
This presentation has not been filed, registered or approved in any jurisdiction.
The information is provided for general information purposes only, without taking
into account any person’s objectives, financial situation or needs.
It should not be relied on by the recipient in considering the merits of any particular
transaction, including the Opportunity. The recipient should consider its own
financial situation, objectives and needs and conduct its own independent
investigation and assessment of the contents of the Information.
Past performance information included in this presentation is provided for
illustrative purposes only, should not be relied upon and is not an indication of
future performance.
Biome Australia Limited (“Company”) and its related bodies corporate, directors,
officers, partners, employees, advisers, consultants and agents make no
representation nor give any warranty, express or implied, as to the accuracy,
completeness, reliability, timeliness or suitability of the information or that the
information may be used in any given way or to achieve any given result.
This presentation contains forward-looking statements, which may be identified by
words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’ or ‘intends’ and other
similar words that connote risks and uncertainties. Certain statements, beliefs, and
opinions contained in this presentation, in particular those regarding the possible
or assumed future financial or other performance, industry growth or other trend
projections are predictions only, and not guarantees, and subject to inherent risks
and uncertainties.
Except to the extent required by law, none of the Company, its Related Persons or
any other person gives any assurance that the results, performance or
achievements expressed or implied by the forward-looking statements contained in
this presentation will actually occur and investors are cautioned not to place undue
reliance on such forward-looking statements.
A summary of the key risks associated with the Company, its business and an
investment in its shares is set out at the end of this presentation. All
forward-looking statements are subject to risk factors, many of which are beyond
the control of the Company and its Related Persons and, if they were to occur, could
cause the Company’s actual financial results to differ materially from the results
expressed or anticipated in the forward-looking statements. The information
should be read in conjunction with the risk factors set out at the end of this
presentation.
The information is based on an assessment of the economic and operating
conditions as at the date of this presentation, and on a number of assumptions
regarding future events and actions that, as at the date of this presentation, are
expected to take place. Except to the extent required by law, the Company and its
Related Parties will not be updating or revising the information.
The recipient must, and agrees with the Company that it will, make its own
independent assessment of the accuracy, completeness, reliability, timeliness and
suitability of the information and its own determination of whether the information
is appropriate to be used for any given purpose. The recipient will rely upon the
information at its own risk.
To the maximum extent permitted by law, the Company and its Related Persons
exclude and disclaim all liability for any loss, damage, cost or expense suffered by
the recipient or any other person arising from or in connection with use or reliance
on (in any manner) the information or the recipient’s participation in the
Opportunity, whether the loss, damage, cost or expense arise because of
negligence, default, misrepresentation or some other cause, and whether or not
foreseeable. To the maximum extent permitted by law, the recipient (on its own
behalf and on behalf of each of its representatives) unconditionally and irrevocably
releases the Company and its Related Persons from all claims and liability. The
Company holds this release for itself and on trust for its Related Persons.
The information contained in this presentation represents the Company’s
strategy as determined by the board of directors as at the date of this
presentation (02 June 2026), and the board reserves its right to change this
strategy and conduct the business of the Company as appropriate having
regard to changes in market or operating conditions.
Share your feedback
Discover